JP5665848B2 - ビタミンd受容体アゴニストとその使用 - Google Patents
ビタミンd受容体アゴニストとその使用 Download PDFInfo
- Publication number
- JP5665848B2 JP5665848B2 JP2012506099A JP2012506099A JP5665848B2 JP 5665848 B2 JP5665848 B2 JP 5665848B2 JP 2012506099 A JP2012506099 A JP 2012506099A JP 2012506099 A JP2012506099 A JP 2012506099A JP 5665848 B2 JP5665848 B2 JP 5665848B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- vida
- ethyl
- pharmaceutically acceptable
- ylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C(CC1)C(C)(CCC2)C1C2=O)OC[C@](C)C(C)(C)O* Chemical compound CC(C(CC1)C(C)(CCC2)C1C2=O)OC[C@](C)C(C)(C)O* 0.000 description 9
- MGMNYFIQDSQPIZ-XWEYMPDHSA-N CCC(CC)(CCCOC(C)C(CC1)C(C)(CCC2)C1/C2=C/C=C1\C[C@@H](C)C2(CC2)CC1)O Chemical compound CCC(CC)(CCCOC(C)C(CC1)C(C)(CCC2)C1/C2=C/C=C1\C[C@@H](C)C2(CC2)CC1)O MGMNYFIQDSQPIZ-XWEYMPDHSA-N 0.000 description 1
- XKQZCBKWFNYMLG-CZVCLPBNSA-N CCC(CC)(CCO[C@H](C)C(CC1)C(C)(CCC2)C1C2O)O Chemical compound CCC(CC)(CCO[C@H](C)C(CC1)C(C)(CCC2)C1C2O)O XKQZCBKWFNYMLG-CZVCLPBNSA-N 0.000 description 1
- XSNYFZBLPPVHEK-UHFFFAOYSA-N COC(CCCO[NH-])=O Chemical compound COC(CCCO[NH-])=O XSNYFZBLPPVHEK-UHFFFAOYSA-N 0.000 description 1
- FUBPRYXDIHQLGH-TWJXAIAZSA-N C[C@@H](CO)C(CC1)C(C)(CCC2)C1C2O Chemical compound C[C@@H](CO)C(CC1)C(C)(CCC2)C1C2O FUBPRYXDIHQLGH-TWJXAIAZSA-N 0.000 description 1
- KKIJMEVZCRQJFP-IHWZXDPASA-N C[C@@H](COC(C(C)(C)C)=O)C(CC1)C(C)(CCC2)C1C2O Chemical compound C[C@@H](COC(C(C)(C)C)=O)C(CC1)C(C)(CCC2)C1C2O KKIJMEVZCRQJFP-IHWZXDPASA-N 0.000 description 1
- WDDSFHNXKMLCRU-NCEGKQKGSA-N C[C@@H](CO[C@H](C)C(CC1)C(C)(CCC2)C1/C2=C/C=C(C[C@H](C1C)O)C[C@H]1O)C(C)(C)O Chemical compound C[C@@H](CO[C@H](C)C(CC1)C(C)(CCC2)C1/C2=C/C=C(C[C@H](C1C)O)C[C@H]1O)C(C)(C)O WDDSFHNXKMLCRU-NCEGKQKGSA-N 0.000 description 1
- ZJRKZZYVVWADND-ZCBKWVDQSA-N C[C@H](COC(C(C)(C)C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1C2O Chemical compound C[C@H](COC(C(C)(C)C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1C2O ZJRKZZYVVWADND-ZCBKWVDQSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17016009P | 2009-04-17 | 2009-04-17 | |
| US61/170,160 | 2009-04-17 | ||
| PCT/US2010/030777 WO2010120698A1 (en) | 2009-04-17 | 2010-04-12 | Vitamin d receptor agonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012524091A JP2012524091A (ja) | 2012-10-11 |
| JP2012524091A5 JP2012524091A5 (cg-RX-API-DMAC7.html) | 2013-05-16 |
| JP5665848B2 true JP5665848B2 (ja) | 2015-02-04 |
Family
ID=42710758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506099A Active JP5665848B2 (ja) | 2009-04-17 | 2010-04-12 | ビタミンd受容体アゴニストとその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120115824A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2419403B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5665848B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102482210B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010236642B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2758698C (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ595727A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010120698A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993547B2 (en) * | 2011-06-14 | 2015-03-31 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
| CN105456278A (zh) * | 2014-09-03 | 2016-04-06 | 欣凯医药科技(上海)有限公司 | 一种抑制食欲的活性维生素d类似物 |
| CN105384765A (zh) * | 2014-09-04 | 2016-03-09 | 欣凯医药科技(上海)有限公司 | 奎宁酸内酯衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1559708A (en) * | 1924-04-11 | 1925-11-03 | Kelsey Walter Harrison | Mattress and method of making the same |
| JP3759639B2 (ja) * | 1994-04-11 | 2006-03-29 | 中外製薬株式会社 | 22−チアビタミン▲d3▼誘導体 |
| JPH10182597A (ja) * | 1996-10-29 | 1998-07-07 | Sumitomo Pharmaceut Co Ltd | 異性化ビタミンd誘導体 |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| WO1998052574A1 (en) * | 1997-05-22 | 1998-11-26 | Cephalon, Inc. | Vitamin d analogues and their neuronal effects |
| GB9819764D0 (en) * | 1998-09-10 | 1998-11-04 | Oxagen Limited | Method |
| IT1311921B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| US6673782B2 (en) * | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| US20030195175A1 (en) * | 2002-03-25 | 2003-10-16 | Deluca Hector F. | Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone |
| EP1559708A4 (en) * | 2002-10-10 | 2006-07-19 | Wisconsin Alumni Res Found | 2,2-DISUBSTITUTED 1A, 25-DIHYDROXY-19-NORVITAMINE D DERIVATIVE |
| WO2004067504A1 (ja) * | 2003-01-31 | 2004-08-12 | Chugai Seiyaku Kabushiki Kaisha | 2位置換ビタミンd誘導体 |
| US6894037B2 (en) * | 2003-07-03 | 2005-05-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses |
| US20050209203A1 (en) * | 2003-07-30 | 2005-09-22 | Jin Tian | Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
| US8377913B2 (en) * | 2007-11-20 | 2013-02-19 | Abbvie Inc. | Vitamin D receptor activators and methods of making |
-
2010
- 2010-04-12 EP EP10714143.4A patent/EP2419403B1/en active Active
- 2010-04-12 JP JP2012506099A patent/JP5665848B2/ja active Active
- 2010-04-12 NZ NZ595727A patent/NZ595727A/xx unknown
- 2010-04-12 AU AU2010236642A patent/AU2010236642B2/en active Active
- 2010-04-12 WO PCT/US2010/030777 patent/WO2010120698A1/en not_active Ceased
- 2010-04-12 CA CA2758698A patent/CA2758698C/en active Active
- 2010-04-12 US US13/264,280 patent/US20120115824A1/en not_active Abandoned
- 2010-04-12 CN CN201080027380.8A patent/CN102482210B/zh active Active
-
2018
- 2018-04-09 US US15/948,359 patent/US20180327354A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012524091A (ja) | 2012-10-11 |
| NZ595727A (en) | 2013-11-29 |
| CA2758698C (en) | 2017-08-08 |
| CA2758698A1 (en) | 2010-10-21 |
| WO2010120698A1 (en) | 2010-10-21 |
| AU2010236642A1 (en) | 2011-11-03 |
| CN102482210A (zh) | 2012-05-30 |
| US20180327354A1 (en) | 2018-11-15 |
| EP2419403A1 (en) | 2012-02-22 |
| CN102482210B (zh) | 2015-04-08 |
| US20120115824A1 (en) | 2012-05-10 |
| AU2010236642B2 (en) | 2014-06-26 |
| EP2419403B1 (en) | 2016-09-07 |
| HK1166493A1 (zh) | 2012-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5544298B2 (ja) | 新規ビタミンd受容体賦活剤および製造方法 | |
| JP2001504135A (ja) | 2−アルキリデン−19−ノル−ビタミンd化合物 | |
| US20180327354A1 (en) | Unnatural Analogues of Calcitriol and Uses Thereof | |
| JP5005340B2 (ja) | 2−プロピリデン−19−ノル−ビタミンd化合物 | |
| JP5770261B2 (ja) | (20S)−2−メチレン−19−ノル−22−ジメチル−1α,25−ジヒドロキシビタミンD3および(20R)−2−メチレン−19−ノル−22−ジメチル−1α,25−ヒドロキシビタミンD3 | |
| EP2714656A2 (en) | (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives | |
| US8664206B2 (en) | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 | |
| NZ562716A (en) | 2-methylene-19-nor-(23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone | |
| JPWO1999043645A1 (ja) | 24−ヒドロキシビタミンd誘導体 | |
| AU2011232562B2 (en) | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25- dihydroxyvitamin D3 | |
| HK1166493B (en) | Vitamin d receptor agonists and uses thereof | |
| AU2010324596A1 (en) | 2-methylene-19,26-nor-(20S)-1alpha-hydroxyvitamin D3 | |
| CN1168726C (zh) | 新的维生素d类似物 | |
| AU2016268399B2 (en) | 1alpha,25-dihydroxy-24,24-difluoro-19-nor-vitamin D3 analogs and their pharmaceutical uses | |
| US20070238712A1 (en) | 19-Nor-Vitamin D Analogs with 1,2 or 3,2 Heterocyclic Ring | |
| ITMI950032A1 (it) | Composti arilalchilenici | |
| HK1086817B (en) | 2- propylidene-19-nor-vitamin d compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130329 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130329 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130828 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140702 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5665848 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |